MYD88 L265P mutation detected by digital PCR as a prognostic factor in patients with diffuse large B-cell lymphoma in rituximab era
Author:
Funder
Kyowa Hakko Kirin
Publisher
Elsevier BV
Subject
Cancer Research,Oncology,Hematology
Reference25 articles.
1. The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities;Pathologists;Pathol. Int.,2000
2. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy;Maurer;J. Clin. Oncol.,2014
3. Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation – an International Primary Central Nervous System Lymphoma Study Group project;Bromberg;Haematologica,2013
4. Absolute peripheral monocyte count at diagnosis predicts central nervous system relapse in diffuse large B-cell lymphoma;Nitta;Haematologica,2015
5. CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP;Schmitz;J. Clin. Oncol.,2016
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Toripalimab plus lenalidomide for central nervous system recurrence in refractory CD5+ diffuse large B-cell lymphoma with MYD88 and CD79B comutation: a case report;Translational Cancer Research;2024-02
2. The Significance and Importance of dPCR, qPCR, and SYBR Green PCR Kit in the Detection of Numerous Diseases;Current Pharmaceutical Design;2024-01
3. Real-world experiences of CNS-directed chemotherapy followed by autologous stem cell transplantation for secondary CNS involvement in relapsed or refractory diffuse large B-cell lymphoma;Frontiers in Oncology;2023-01-19
4. Enhanced lipid metabolism confers the immunosuppressive tumor microenvironment in CD5-positive non-MYC/BCL2 double expressor lymphoma;Frontiers in Oncology;2022-10-06
5. SGK1mutation status can further stratify patients with germinal center B‐cell‐like diffuse large B‐cell lymphoma into different prognostic subgroups;Cancer Medicine;2022-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3